Foghorn Therapeutics Halted Drug Program, Cut Staff
The firm abandoned its oncology candidate FHD-909 after clinical trials failed to demonstrate sufficient efficacy.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you plan to continue investing in early-stage biotechnology companies for your portfolio?
Foghorn Therapeutics terminated the joint development of the lung cancer candidate FHD-909 with Eli Lilly following disappointing phase 1 trial results. Consequently, the company has initiated a strategic reprioritization that includes a 40 percent reduction in its workforce.
Why it matters
The failure underscores the difficulty of translating SMARCA2/4 synthetic lethality research into successful clinical outcomes for lung cancer treatments. This decision forces a major shift in the company’s operating model to preserve cash.
The FHD-909 oncology candidate failed to meet efficacy benchmarks required to advance from phase 1 to the clinical expansion stage. The company reported that the intended SMARCA2/4 synthetic lethality—a mechanism where the loss of two genes simultaneously becomes fatal to cancer cells—did not manifest at the levels necessary for further development.
The players
Foghorn Therapeutics
A biotechnology company focused on developing therapies that target chromatin regulatory systems to treat cancer.
Eli Lilly
A multinational pharmaceutical firm with a large-scale oncology pipeline that collaborates on early-stage drug discovery.
The details
The program relied on a synthetic lethality approach, which targets specific gene dependencies in tumors to kill cancer cells while sparing healthy tissue. Because FHD-909 failed to achieve the necessary biological response during initial trials, the company has halted all clinical development for this candidate. The board’s strategic pivot seeks to extend the company's remaining cash runway into the second half of 2029.
Timeline
September 30, 2026: The board approved the strategic reprioritization and staff cuts.
October 1, 2026: The company formally announced the termination of the drug program and the layoffs.
Second half of 2029: The company anticipates its current cash reserves will last until this time.
The Tech Race
This program termination follows a pattern set by previous unsuccessful attempts to capitalize on SMARCA2/4 synthetic lethality in clinical settings. The failure highlights the significant gap remaining between promising genomic research and the delivery of effective cancer therapeutics.
Investors saw share prices fall 44 percent to $2.00 during Thursday premarket trading following the announcement. For employees, the 40 percent workforce reduction significantly limits the company to a remaining team of 65, shifting its focus exclusively toward extending its cash runway through 2029.
The takeaway
The abandonment of FHD-909 represents a major setback for the company’s internal oncology development efforts. Market observers should watch the firm's next financial disclosure to see if the reduced staff and extended cash runway successfully stabilize operations.
Further reading
For more context on current developments in drug discovery, visit Biotech.
Live Poll
Do you plan to continue investing in early-stage biotechnology companies for your portfolio?
